+41 91 682 20 40
info@elixi-int.com
Reserved Area

Home
About Us
Services
Quality
News
Case Studies
Contact
Online Store

Let's talk

info@yourwebsite.com
+1 (555) 123-4567

Search

neurofibromatosis

13 April 2020

Koselugo (selumetinib), newly approved treatment of neurofibromatosis type 1 (NF1)